Evolus posts record FY2024 revenue $266.3M (+32%); guides 2025 $345-355M; FDA for HA gels within 90 days

Evolus, Inc.

2024-FY EPS reported -$0.81 revenue$266,274,000

Preliminary Q4 2024 net revenue $79.0M (+30% YoY); FY2024 net revenue $266.3M (+32% YoY) at top of guidance ($260-266M).
Expects FDA approval within 90 days for Evolysse Form and Smooth HA gels; US launch planned Q2 2025, a quarter ahead of prior timeline.
2025 revenue guidance $345-355M (30-33% growth); non-GAAP operating expenses $230-240M; positive non-GAAP operating income expected for full-year 2025.
Cash and equivalents $87M as of Dec 31, 2024, up from $85M on Sep 30; >15,300 accounts purchasing Jeuveau since launch.
Evolus Rewards enrollment grew over 40% to ~1.1M; Q4 redemptions record ~220,000, with ~60% from repeat treatments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.